EUCTR2009-016151-21-IT进行中（未招募）1 期
A randomized multicentre phase II trial with pazopanib and weekly paclitaxel vs weekly paclitaxel in platinum resistant or refractory ovarian cancer - MITO - 11
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE0 个研究点目标入组 72 人开始时间: 2009年12月21日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •? Cytologic / histologic diagnosis of stage IC-IV ovarian cancer ? Disease progressed during first line chemotherapy or disease relapsed within 6 months after the last platinum treatment ? Disease evaluable by RECIST or Ca 125 GCIG criteria ? No residual peripheral neurotoxicity from previous chemotherapy treatment ? PS 0-1 ? Age ? 18 and < 75 years. ? Life expectancy of at least 3 months ? Able to swallow and retain oral medication ? Written informed consent prior to performance of study specific procedures or assessments ? Ability and willingness to comply with treatment and follow up assessments and procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •? Previous or concomitant malignant neoplasia (not including basocellular or spinocellular skin carcinoma or in-situ carcinoma of the uterine cervix, provided they are being adequately treated) ? Previous treatment with weekly paclitaxel ? More than 2 previous chemotherapy treatments ? Serious heart disease, including heart failure, atrioventricular block of any degree, serious arrhythmia or history of any one or more of the following cardiovascular conditions within the past 6 months: cardiac angioplasty or stenting, myocardial infarction, unstable angina, symptomatic peripheral vascular disease, coronary artery by-pass graft surgery, class II, III or IV congestive heart failure as defined by the New York Heart Association (NYHA) ? Hemoglobin < 9 g/dL, neutrophils < 1500/mm3, platelets < 100000/mm3 ? Impairment of renal function (patients should have 2 functioning kidneys): creatinine ? 1.5 times the upper normal limit UNL; calculated creatinine clearance < 50 mL/min; urine protein to creatinine ratio ? 1: then, a 24-hour urine protein must be assessed and subject must have a 24-hour urine protein value <1gr to be eligible ? Impairment of liver function (SGOT or SGPT ? 2.5 UNL, alkaline phosphatase > 2.5 ULN, total bilirubin > 1.5 times the UNL) ? Prothrombin time (PT) or international normalized ratio (INR) or activated partial thromboplastin time (PTT) > 1.2 times the UNL ? Pregnancy, breast feeding, or inadequate contraception ? Unable to discontinue prohibited medications (see protocol section 6.7) ? Clinically significant gastrointestinal abnormalities which might interfere with oral dosing, including but not limited to malabsorption syndrome, major resection of the stomach or small bowel that could affect drug absorption, active peptic ulcer disease, inflammatory bowel disease, ulcerative colitis, other gastrointestinal conditions with increased risk of perforation, history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment, signs or symptoms of GI obstruction ? Any unstable or serious concurrent condition ? Prolongation of corrected QT interval (QTc) >480 ms ? History of cerebrovascular accident, pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months ? Macroscopic hematuria ? Major surgery or trauma within 30 days ? Hypertension uncontrolled with adequate therapy (systolic blood pressure (BP) of ? 140mmHg, or diastolic BP of ? 90mmHg) ? Any ongoing toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity ? Present or suspected haemorrhagic syndromes ? Patients` inability to access the centre due to area of residence
研究者
相似试验
已完成
2 期
An open-label multicenter phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer.endometrial canceruterine corpus carcinoma10046828NL-OMON39290Academisch Medisch Centrum55
进行中（未招募）
1 期
A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. - PALETTESoft Tissue SarcomaMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-001307-33-BEGlaxoSmithKline Research & Development Limited360
进行中（未招募）
不适用
A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. - PALETTESoft Tissue SarcomaMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-001307-33-DKGlaxoSmithKline Research & Development Limited360
进行中（未招募）
不适用
A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. - PALETTESoft Tissue SarcomaMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-001307-33-SEGlaxoSmithKline Research & Development Limited360
进行中（未招募）
1 期
A randomized double blind phase III trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or following prior therapy. Ensayo fase III aleatorizado y doble ciego de pazopanib frente a placebo en pacientes con sarcoma de tejidos blandos cuya enfermedad ha progresado durante o tras tratamiento previo. - PALETTESoft Tissue SarcomaSarcoma de tejidos blandosMedDRA version: 9.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasEUCTR2008-001307-33-ESGlaxoSmithKline, S.A.